Pfizer

As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod
Fierce Pharma
Mon, 12/16/19 - 10:37 pm
Pfizer
Astellas
Xtandi
prostate cancer
JNJ
Erleada
FDA
FDA Approves Pfizer's Extended Release Xeljanz for Ulcerative Colitis
BioSpace
Fri, 12/13/19 - 12:21 pm
Pfizer
Xeljanz XR
FDA
ulcerative colitis
Pfizer to debut podcast series around vaccines, probing scientific, cultural and political issues
Fierce Pharma
Wed, 12/11/19 - 10:30 am
Pfizer
vaccines
podcasts
drug marketing
Sangamo keeps pressure on rivals with updated hemophilia data
Biopharma Dive
Sat, 12/7/19 - 11:48 pm
ASH2019
Pfizer
Sangamo
hemophilia
SB-525
An old, controversial Pfizer drug shows mid-stage efficacy against narcolepsy
Endpoints
Wed, 12/4/19 - 10:37 am
Pfizer
narcolepsy
reboxetine
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Reuters
Wed, 11/27/19 - 12:36 pm
gene therapy
drug manufacturing
Pfizer
Novartis
Bluebird Bio
PTC Therapeutics
Krystal Biotech
Takeda sets sights on first-line lung cancer market with new Alunbrig data
Pharmaforum
Mon, 11/25/19 - 09:49 am
Takeda
Alunbrig
clinical trials
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori
Fierce Pharma
Sat, 11/23/19 - 04:12 pm
Pfizer
Xalkori
ALK-positive non-small cell lung cancer
Takeda
Alunbrig
Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You
Motley Fool
Sat, 11/23/19 - 04:11 pm
Pfizer
Vyndaqel
ATTR-CM
Eidos Therapeutics
AG10
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Motley Fool
Wed, 11/20/19 - 10:02 am
Amarin
Vascepa
M&A
Amgen
Novartis
Pfizer
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
Tue, 11/19/19 - 11:38 pm
earnings
Big Pharma
AstraZeneca
Merck
Celgene
Novartis
Novo Nordisk
Pfizer
Top 10 pharma settlements since 2018
Fierce Pharma
Tue, 11/19/19 - 10:27 am
settlements
Reckitt Benckiser
JNJ
Bayer
Allergan
Actelion
Purdue Pharma
Teva Pharmaceutical
Endo
Teikoku
Insys
Pfizer
GSK
Astellas
Amgen
FDA approves latest Humira near-copy, as dozens of biosimilars head for market
Pharmaforum
Mon, 11/18/19 - 10:11 am
FDA
Pfizer
biosimilars
Humira
AbbVie
Abrilada
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Fierce Pharma
Sun, 11/17/19 - 08:50 pm
Pfizer
Eliquis
Bristol-Myers Squibb
atrial fibrillation
Pfizer's Xeljanz gets EMA blood clots warning following FDA's similar move
Fierce Pharma
Sat, 11/16/19 - 10:27 pm
Europe
EMA
ulcerative colitis
Pfizer
Xeljanz
Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?
Fierce Pharma
Tue, 11/12/19 - 07:57 pm
Mylan
Pfizer
Upjohn
M&A
generics
Viatris
Pfizer's 'brainstorming' payment deals as gene therapies advance
Fierce Pharma
Fri, 11/8/19 - 12:11 pm
Pfizer
gene therapy
outcomes-based pricing
Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial
Marketwatch
Fri, 11/8/19 - 10:45 am
Merck KGaA
Pfizer
Bavencio
clinical trials
gastric cancer
Think Mylan's done with M&A after its Pfizer deal? Think again
Fierce Pharma
Tue, 11/5/19 - 11:49 pm
Mylan
Pfizer
M&A
Upjohn
generics

Pages